CryoLife, Inc. (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $22.00, for a total value of $22,000.00. Following the completion of the sale, the director now directly owns 101,849 shares in the company, valued at approximately $2,240,678. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

CryoLife, Inc. (CRY) traded down 0.23% during mid-day trading on Friday, reaching $22.00. The company’s stock had a trading volume of 85,918 shares. The stock has a market cap of $735.81 million, a PE ratio of 66.67 and a beta of 0.97. The company has a 50 day moving average of $19.39 and a 200-day moving average of $18.13. CryoLife, Inc. has a 52-week low of $14.02 and a 52-week high of $22.85.

CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.13 earnings per share. Equities analysts forecast that CryoLife, Inc. will post $0.43 earnings per share for the current year.

WARNING: “C Elkins Ronald Sells 1,000 Shares of CryoLife, Inc. (CRY) Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/08/c-elkins-ronald-sells-1000-shares-of-cryolife-inc-cry-stock.html.

A number of analysts have issued reports on CRY shares. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $22.00.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of CryoLife by 16.5% in the 1st quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock valued at $517,000 after purchasing an additional 4,399 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of CryoLife by 4.6% in the 1st quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock valued at $2,714,000 after purchasing an additional 7,228 shares in the last quarter. Dialectic Capital Management LP acquired a new stake in shares of CryoLife in the 1st quarter valued at $2,238,000. Vanguard Group Inc. boosted its holdings in shares of CryoLife by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after purchasing an additional 43,212 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in shares of CryoLife by 1.9% in the 1st quarter. Louisiana State Employees Retirement System now owns 11,000 shares of the medical equipment provider’s stock valued at $183,000 after purchasing an additional 200 shares in the last quarter. 68.85% of the stock is currently owned by hedge funds and other institutional investors.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.